Table 4. Characteristics of the patients and the distribution of risk factors.
| Author/year | Treatment | Age (y) | Male, n (%) | SBP (mmHg, before treatment) | SBP (mmHg, after treatment) | DBP (mmHg, before treatment) | DBP (mmHg, after treatment) | Diabetes mellitus, n (%) | Dyslipidemia, n (%) | Current smokers, n (%) | Former smokers, n (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Neuman et al., 2016 [13] | Nebivolol | 51 ± 8.6 | 13 (68.4) | 135 ± 15 | 81 ± 14 | 1 (5.3) | 6 (31.5) | 7 (36.8) | |||
| Metoprolol | 51 ± 8.6 | 13 (68.4) | 134 ± 15 | 81 ± 21 | 1 (5.3) | 6 (31.5) | 7 (36.8) | ||||
| Sendur et al., 2014 [11] | Nebivolol | 50.1 ± 9.4 | 11 (25.6) | 151.2 ± 4.1 | 132.3 ± 9.6 | 93.9 ± 2.5 | 84.8 ± 6.4 | 11 (25.6) | 4 (9.3) | ||
| Olmesartan | 54.9 ± 7.9 | 19 (45.2) | 154.2 ± 4.0 | 131.4 ± 11.8 | 94.9 ± 2.4 | 83.2 ± 2.4 | 11 (26.2) | 9 (21.4) | |||
| Zepeda et al., 2012 [20] | Nebivolol | 44.9 ± 2.1 | 15 (71.4) | 141 ± 6.3 | −17.41 | 98.7 ± 5.2 | −13.71 | ||||
| Carvedilol | 45.6 ± 2.8 | 16 (69.6) | 139 ± 5.1 | −19.91 | 97.3 ± 6.6 | −12.81 | |||||
| Espinola-Klein et al., 2011 [21] | Nebivolol | 66.7 ± 8.3 | 45 (86.5) | 147.6 ± 6.6 | −5.21 | 79.6 ± 7.4 | −1.71 | 17 (32.7) | 31 (59.6) | 15 (28.8) | 33 (63.5) |
| Metoprolol | 65.9 ± 7.9 | 41 (71.9) | 147.6 ± 6.6 | −3.91 | 81.4 ± 7.6 | −2.51 | 12 (21.1) | 39 (68.4) | 19 (33.3) | 29 (50.9) | |
| Fedorishina et al., 2010 [22] | Nebivolol | 30–55 | 1–2 grades | 1–2 grades | |||||||
| Carvedilol | 30–55 | 1–2 grades | 1–2 grades | ||||||||
| Pronko et al., 2009 [14] | Nebivolol | 10 (43.5) | 2–3 grades | 2–3 grades | 0 (0) | 0 (0) | 0 (0) | ||||
| Atenolol | 14 (48.3) | 2–3 grades | 2–3 grades | 0 (0) | 0 (0) | 0 (0) | |||||
| Simova et al., 2009 [26] | Nebivolol | 45.3 ± 11.5 | 18 (72.0) | 152.4 ± 18.5 | 131.8 ± 11.5 | 99.3 ± 9.3 | 82.4 ± 7.1 | 0 (0) | 7 (28.0) | 7 (28.0) | 4 (16.0) |
| Bisoprolol | 45.3 ± 11.5 | 18 (72.0) | 152.4 ± 18.5 | 129.7 ± 10.2 | 99.3 ± 9.3 | 83.1 ± 7.0 | 0 (0) | 7 (28.0) | 7 (28.0) | 4 (16.0) | |
| Pasini et al., 2008 [23] | Nebivolol | 55.9 ± 10.0 | 8 (40.0) | 152.4 ± 8.1 | 133.0 ± 7.2 | 96.1 ± 4.3 | 85.0 ± 3.1 | ||||
| Atenolol | 55.9 ± 10.0 | 8 (40.0) | 151.8 ± 7.7 | 134.2 ± 5.1 | 96.5 ± 5.1 | 85.8 ± 3.6 | |||||
| Ghiadoni et al., 2003 [24] | Nebivolol | 53 ± 8 | 17 (60.7) | 152 ± 9 | 136 ± 10 | 98 ± 9 | 84 ± 6 | 0 (0) | |||
| Nifedipine GITS | 52 ± 11 | 17 (60.7) | 153 ± 8 | 137 ± 11 | 102 ± 2 | 87 ± 5 | 0 (0) | ||||
| Amlodipine | 53 ± 8 | 17 (60.7) | 152 ± 9 | 136 ± 10 | 98 ± 9 | 84 ± 6 | 0 (0) | ||||
| Atenolol | 53 ± 9 | 18 (62.1) | 156 ± 10 | 136 ± 10 | 99 ± 8 | 84 ± 6 | 0 (0) | ||||
| Telmisartan | 50 ± 9 | 18 (62.1) | 151 ± 10 | 133 ± 10 | 100 ± 7 | 86 ± 5 | 0 (0) | ||||
| Perindopril | 51 ± 11 | 18 (64.3) | 153 ± 9 | 134 ± 10 | 100 ± 6 | 86 ± 6 | 0 (0) | ||||
| Tzemos et al., 2001 [25] | Nebivolol | 52 ± 7 | 154 ± 8 | 132 ± 7 | 98 ± 9 | 82 ± 6 | 0 (0) | 0 (0) | 0 (0) | ||
| Atenolol | 52 ± 7 | 154 ± 8 | 132 ± 9 | 98 ± 9 | 83 ± 4 | 0 (0) | 0 (0) | 0 (0) |
1
Absolute change in blood pressure.